Dr. Ashkan Emadi

University of Maryland, USA



2004 Ph.D., Illinois Institute of Technology, Chemistry

1996 M.D., Tehran University of Medical Sciences, Medicine

Publications (selected)

  1. Emadi A, Pakbaz Z, Koorosdari H, Farhadi M, Pasalar P, Malekpoor H, Fayazmoghaddam K. Results of screening program forb-thalassemia trait on 8500 high school students in Tehran. Iran Thalassemia Association Journal. 1997; 12: 53-55.
  2. Pakbaz Z,Emadi A, Moghaddam KF, Farhadi M, Malekpoor H, Pasalar P. Assessing the level of knowledge in high school students in Tehran about thalassaemia and the evaluation of an educational program. Thalassemia International Federation News. 1999; 28(11): 15-17.
  3. Emadi A, Harwood JS, Kohanim S, Stagliano KW. Regiocontrolled Synthesis of the Trimeric Quinone Framework of Conocurvone. Organic Letters.2002;4(4): 521-524.
  4. Stagliano KW, Lu Z,Emadi A, Harwood JS, Harwood CA. Effect of Methoxyl Group Position on the Regioselectivity of Ammonia Substitution Reactions Involving 3,3'-Dichloro-2,2'-binaphthoquinones.Journal of Organic Chemistry. 2004; 69(15): 5128-5131.
  5. Stagliano KW, Emadi A*, Lu Z, Malinakova HC, Twenter B, Yu M, Holland LE, Rom AM, Harwood JS, Amin R, Johnson AA, Pommier Y. Regiocontrolled synthesis and HIV inhibitory activity of unsymmetrical binaphthoquinone and trimeric naphthoquinone derivatives of conocurvone. Bioorganic and Medicinal Chemistry. 2006; 14(16): 5651-5665.
  6. Emadi A, Burns KH, Confer B, Borowitz MJ, Streiff MB. Hematological manifestations of nephropathic cystinosis.Acta Haematologica. 2008;119 (3): 169-172.
  7. Segal JB, Brotman DJ, Necochea AJ,Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. The Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults with Venous Thromboembolism and in Family Members of Those with a Mutation: A Systematic Review of the Literature. JAMA. 2009; 301(23): 2472-2485.
  8. Emadi A, Spivak JL. Anagrelide: 20 years later.Expert Review of Anticancer Therapy. 2009; 9(1): 37-50.
  9. Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria.American Journal of Hematology. 2009; 84(10): 699-701.
  10. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and Cancer: Golden Anniversary. Nature Reviews Clinical Oncology. 2009; 6(11): 638-647.
  11. Emadi A, Crim MT, Brotman DJ, Necochea AJ, Samal L, Wilson LM, Bass EB, Segal JB. Analytic Validity of Genetic Tests to Identify Factor V Leiden and Prothrombin G20210A.American Journal of Hematology.2010; 85(4): 264-270.
  12. Antonarakis ES,Emadi A. Ruthenium-based Chemotherapeutics: Are they ready for prime time?Cancer Chemotherapy and Pharmacology.2010; 66(1): 1-9.
  13. Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. A Chemical Genetic Screen for Modulators of Asymmetrical 2,2´-Dimeric Naphthoquinone Cytotoxicity in Yeast.PLoS One. 2010May 26; 5(5):e10846.
  14. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered.Blood Review. 2010;24(4-5):191-199.
  15. Ross AE,Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M. Dimeric naphthoquinones represent a novel class of compounds with prostate cancer cytotoxicity. British Journal of Urology International. 2011; 108(3): 447-454.
  16. Emadi A, Streiff MB. Diagnosis and Management of Venous Thromboembolism: An Update A Decade into the New Millennium. Archives of Iranian Medicine.2011; 14 (5): 341-351.
  17. Emadi A, Streiff MB. Management of Acquired Thrombophilic Disorders in 2011: Focus on Heparin-induced Thrombocytopenia, Antiphospholipid Syndrome, Myeloproliferative Neoplasms, and Paroxysmal Nocturnal Hemoglobinuria. Archives of Iranian Medicine.2011; 14 (6): 401-411.
  18. Emadi A, Le A, Harwood CA, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M. Metabolic and Electrochemical Mechanisms ofDimeric Naphthoquinones Cytotoxicity in Breast Cancer Cells.Bioorganic and Medicinal Chemistry. 2011; 19(23): 7057-7062.
  19. Kamangar F,Emadi A. Vitamin and Mineral Supplements: Do We Really Need Them? International Journal of Preventive of Medicine. 2012; 3: 221-6.
  20. Emadi A, Karp JE.The Clinically Relevant Pharmacogenomic Changes in Acute Myelogenous Leukemia. Pharmacogenomics. (in press)